BRIEF-Spartannash Acquiring Fresh Encounter Inc-March 2024-www.financetom.com

BRIEF-Spartannash Acquiring Fresh Encounter Inc

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Spartannash Acquiring Fresh Encounter Inc

Oct 17, 2024 2:53 PM

Oct 14 (Reuters) - SpartanNash Co ( SPTN ):

* SPARTANNASH ACQUIRING FRESH ENCOUNTER INC., GROWING RETAIL

FOOTPRINT BY 33%

* SPARTANNASH CO ( SPTN ) - TERMS OF DEAL WERE NOT DISCLOSED

Source text for Eikon:

Further company coverage:

Previous page： BRIEF-Ardent Health Partners, Inc Files For IPO Of Common Stock- SEC Filing Next page： Athletics-Lyles brings star power to track at US trials

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-Ardent Health Partners, Inc Files For IPO Of Common Stock- SEC Filing

Jun 21, 2024

Ardent Health Partners LLC: * ARDENT HEALTH PARTNERS, INC FILES FOR IPO OF COMMON STOCK- SEC FILING * ARDENT HEALTH PARTNERS, INC.: APPLIED TO LIST COMMON STOCK ON THE NEW YORK STOCK EXCHANGE UNDER THE SYMBOL ARDT * ARDENT HEALTH PARTNERS, INC: J.P. MORGAN, BOFA SECURITIES, MORGAN STANLEY, STEPHENS INC., CITIGROUP ARE UNDERWRITERS FOR IPO * ARDENT HEALTH PARTNERS, INC.:...

Athletics-Lyles brings star power to track at US trials

Jun 21, 2024

NEW YORK, June 21 (Reuters) - Noah Lyles wants to stamp out his territory on and off the track ahead of the Paris Games, as the 100 metres world champion begins his latest U.S. Olympic trials campaign this week with enormous expectations on his shoulders. A speedy 9.85 second performance in the 100 metres earlier this month in Kingston saw...

Ardent Health makes US IPO filing public

Jun 21, 2024

June 21 (Reuters) - Ardent Health Partners on Friday made public its paperwork for an initial public offering in the United States. ...

Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar

Jun 21, 2024

June 21 (Reuters) - Amylyx Pharmaceuticals ( AMLX ) has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals' ( EIGRQ ) experimental drug for low blood sugar in a $35.1 million deal, Eiger said in a filing on Friday. Amylyx's acquisition of avexitide would mean a foray into drug development for metabolic diseases. The company had so far...